Core Insights - GSK's experimental drug for chronic hepatitis B infection has successfully met the main goals in two significant studies, indicating progress towards a potential functional cure for patients [1] Company Summary - GSK is advancing its research in chronic hepatitis B treatment with promising results from its experimental drug [1]